Meet an Unreasonable Venture

Craif

Realising a society where people can live out their natural lives.

Ryuichi Onose

Cofounder & CEO at Craif

More about Ryuichi »

Connect

craif.comen/

Employees 51–100

Headquarters Tokyo, Japan

Craif is a liquid biopsy startup working on early cancer detection—utilizing its proprietary AI-powered, urine-based microRNA assay technology.

Their flagship product, miSignal, is a commercialized multi-cancer early detection test covering 10 cancer types including pancreatic cancer, generating strong recurring revenue in Japan.

As of April 2026, it is adopted by 2,400+ medical institutions and 5,000+ pharmacies, with projected 2026 revenue of $33M and about 300% YoY growth.

In parallel, they are working on clinical trials to get regulatory approval and reimbursement for pancreatic cancer, targeting PMDA approval in 2027.

Craif is expanding their business to the US and their CEO Ryuichi Onose has relocated to San Diego. They are now working on acquiring MolDX-based CMS reimbursement for pancreatic cancer with the experienced expert team.

Health

Notable Achievements

88,000+ tests sold in Japan with >50% repeat user rate and >300% YoY revenue growth in FY25
92.9% sensitivity & specificity for Stage I/IIA pancreatic cancer in clinical validation
Pancreatic cancer clinical trial for PMDA (equivalent to FDA) to be approved on 2026

Currently Operating in One Region

Unreasonable Stories Podcast

Subscribe for More Videos »

Press Mentions

August 21, 2026

Craif raises US$33M to get its urine cancer test into American clinics

Craif has successfully raised $33 million in a Series D funding round to expedite the introduction of its innovative urine-based cancer detection test in American clinics. This financial boost...

Read on Mugglehead Investment Magazine »

August 19, 2026

Craif raises USD 33M in Series D round

Craif successfully raised $33 million in a Series D funding round, enabling the company to expedite the introduction of its innovative urine-based cancer test in the U.S. This positive development...

Read on Medical Buyer »

August 18, 2026

Craif Raises $33M to Accelerate Introduction of Its Urine-Based Cancer Test to the U.S.

Craif has successfully raised $33 million in Series D funding to expedite the launch of its innovative urine-based cancer test in the United States. This significant investment underscores Craif's...

Read on GlobeNewswire News Room »

April 29, 2025

Craif Secures $22M for Early Cancer Detection Technology - The Singular Ai

Craif, an innovative startup focused on early cancer detection, has successfully secured $22 million in funding. This investment will enable Craif to expand its groundbreaking urine biopsy...

Read on The Singular Ai »

April 28, 2025

Early cancer detection startup Craif raises $22M

Cancer ranks as one of the top causes of death worldwide. The National Cancer Institute reported nearly 20 million new cancer cases and 9.7 million

Read on TechCrunch »

May 27, 2024

Unreasonable Impact announces new roster of ventures for Asia Pacific programme

The story discusses the launch of a new online platform called "The Good Influence" that aims to promote positive content and combat misinformation on social media. It highlights the platform's...

Read on WebWire »